Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Operating Leases (2022 - 2025)

Historic Operating Leases for Treace Medical Concepts (TMCI) over the last 4 years, with Q3 2025 value amounting to $12.9 million.

  • Treace Medical Concepts' Operating Leases fell 2157.46% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 2157.46%. This contributed to the annual value of $15.9 million for FY2024, which is 27.06% up from last year.
  • As of Q3 2025, Treace Medical Concepts' Operating Leases stood at $12.9 million, which was down 2157.46% from $13.4 million recorded in Q2 2025.
  • Treace Medical Concepts' 5-year Operating Leases high stood at $19.0 million for Q3 2022, and its period low was $12.9 million during Q3 2025.
  • Its 4-year average for Operating Leases is $15.8 million, with a median of $15.9 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 465.46% in 2024, then plummeted by 2157.46% in 2025.
  • Quarter analysis of 4 years shows Treace Medical Concepts' Operating Leases stood at $15.5 million in 2022, then grew by 2.27% to $15.9 million in 2023, then rose by 0.27% to $15.9 million in 2024, then fell by 18.85% to $12.9 million in 2025.
  • Its Operating Leases stands at $12.9 million for Q3 2025, versus $13.4 million for Q2 2025 and $13.9 million for Q1 2025.